The Swiss Malaria Group members are operating in almost all malaria endemic countries. With their commitment they are contributing to the global fight against malaria. For more information on our members, please go to the member's website by clicking on the member's logo.
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women. Multi-country clinical trial to evaluate the performance of HS-RDT for the detection of malaria infection during pregnancy. Sample size is approximately 900 participants in each country.
1,800 persons
2018 - 2019
Diagnosis,Innovation
Multi-site clinical evaluation of novel malaria diagnostic tools in malaria-endemic countries to assess their clinical performance for detection of malaria at point-of-care (POC). This study supported product development efforts and provided early stage (TRL~5) technology developers with valuable information on performance and basic feasibility data that helped accelerate development.
Clinical performance of Abbott NxTekTM RDTs for detection of Plasmodium infections in patients with symptoms suggestive of malaria to support submission to WHO prequalification.
Clinical performance of RapiGEN BIOCREDIT Malaria Ag RDTs for detection of Plasmodium infections in patients with symptoms suggestive of malaria to support submission to WHO prequalification.
A host antibody marker of past P. vivax infection is targeted in a lateral flow assay in development by Mologic (UK). Clinical studies with partners in Indonesia and Australia will evaluate the assay performance in two longitudinal cohort studies monitoring P. vivax clinical exposure and relapse events.
indonesia united-kingdom japan australia
1,180 persons
2015 - ongoing
Innovation,Diagnosis
A multi-laboratory assessment of the G6PD STANDARD test (SD Biosensor, South Korea) to evaluate assay repeatability and reproducibility across users and settings. The study uses lyophilised controls to ensure standardized samples are used across all sites, so findings should be validated in fresh samples.
bangladesh brazil indonesia united-states thailand france
Control samples only
2020-2021
Innovation,Diagnosis